Norway Large Molecule Drug Substance Cdmo Market Size & Outlook
Norway large molecule drug substance cdmo market, 2018-2030 (US$M)
Related Markets
Norway large molecule drug substance cdmo market highlights
- The Norway large molecule drug substance cdmo market generated a revenue of USD 34.1 million in 2023 and is expected to reach USD 58.9 million by 2030.
- The Norway market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
- In terms of segment, contract manufacturing was the largest revenue generating service in 2023.
- Contract Development is the most lucrative service segment registering the fastest growth during the forecast period.
Large molecule drug substance cdmo market data book summary
| Market revenue in 2023 | USD 34.1 million |
| Market revenue in 2030 | USD 58.9 million |
| Growth rate | 8.1% (CAGR from 2023 to 2030) |
| Largest segment | Contract manufacturing |
| Fastest growing segment | Contract Development |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Contract Manufacturing, Contract Development |
| Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global large molecule drug substance cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany large molecule drug substance cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 1,936.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Large Molecule Drug Substance CDMO Market Scope
Large Molecule Drug Substance CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway large molecule drug substance cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67.16% in 2023. Horizon Databook has segmented the Norway large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
With diverse capabilities in treatments and diagnostics in important fields, such as cancer and neurosciences, Norway has a developing pharmaceutical sector. Due to its long history in the biomedical sciences, Norway is a preferable place for businesses looking to set up a base or collaborate.
Norway can provide pharmaceutical companies with access to high-quality and well-supported research. Initiatives like the Nordic Centers of Excellence (NCoE), Norwegian Centers of Expertise (NCE), and Centers for Research-based Innovation have been established across the nation.
Reasons to subscribe to Norway large molecule drug substance cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway large molecule drug substance cdmo market databook
-
Our clientele includes a mix of large molecule drug substance cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway large molecule drug substance cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Norway large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway large molecule drug substance cdmo market size, by service, 2018-2030 (US$M)
Norway Large Molecule Drug Substance CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
